

Strengths:

1. Diverse Membership (Regulators and Industry Representatives)
2. Members well verse with latest developments in the field.
3. Regular updates through quarterly calls and mails

Weakness:

1. Need more representation from Clinical research Industry.
2. More active participation required from members apart from steering committee

Opportunities

1. The number of clinical studies in Asia Pacific is increasing in line with economic growth.
2. This is the opportunity to set standards and create an environment for successful clinical research for the region.

Threats

1. Still a large chunk of countries unregulated from the perspective of clinical research
2. Focus on Post market surveillance is still to develop.